Six-month treatment with sorbinil in asymptomatic diabetic neuropathy: failure to improve abnormal nerve function
CN Martyn, W Reid, RJ Young, DJ Ewing, BF Clarke - Diabetes, 1987 - Am Diabetes Assoc
CN Martyn, W Reid, RJ Young, DJ Ewing, BF Clarke
Diabetes, 1987•Am Diabetes AssocThe effect of long-term treatment with the aldose reductase inhibitor sorbinil (125 mg daily
for 6 mo) was examined in 22 diabetic patients with subclinical abnormalities of nerve
function. This was a placebo-controlled, double-blind crossover trial in which each of the two
treatment periods lasted 6 mo. Peripheral nerve function was assessed
electrophysiologically and by quantitative sensory testing; autonomie function was assessed
by measurement of five cardiovascular reflexes and of mean heart rate from a 24-h ECG …
for 6 mo) was examined in 22 diabetic patients with subclinical abnormalities of nerve
function. This was a placebo-controlled, double-blind crossover trial in which each of the two
treatment periods lasted 6 mo. Peripheral nerve function was assessed
electrophysiologically and by quantitative sensory testing; autonomie function was assessed
by measurement of five cardiovascular reflexes and of mean heart rate from a 24-h ECG …
The effect of long-term treatment with the aldose reductase inhibitor sorbinil (125 mg daily for 6 mo) was examined in 22 diabetic patients with subclinical abnormalities of nerve function. This was a placebo-controlled, double-blind crossover trial in which each of the two treatment periods lasted 6 mo. Peripheral nerve function was assessed electrophysiologically and by quantitative sensory testing; autonomie function was assessed by measurement of five cardiovascular reflexes and of mean heart rate from a 24-h ECG recording. Measurement of erythrocyte sorbitol concentrations demonstrated very significant inhibition of aldose reductase activity with sorbinil treatment, but no concomitant improvement in either peripheral or autonomie nerve function was observed.
Am Diabetes Assoc